Vera Therapeutics (VERA) Income from Non-Controlling Interests (2021 - 2023)

Vera Therapeutics' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at $29.8 million for Q1 2023.

• Quarterly Income from Non-Controlling Interests rose 74.59% year-over-year to $29.8 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $136.2 million (up 524.57% YoY) and the FY2022 annual result came in at $89.3 million, changed N/A from the prior year.
• Income from Non-Controlling Interests was $29.8 million for Q1 2023 at Vera Therapeutics, down from $146.2 million in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $146.2 million in Q4 2022 and bottomed at -$24.8 million in Q3 2022.
• A 3-year average of $18.1 million and a median of $4.7 million in 2021 frame the typical range for Income from Non-Controlling Interests.
• Peak annual rise in Income from Non-Controlling Interests reached 827.4% in 2022, while the deepest fall reached 336.22% in 2022.
• Vera Therapeutics' Income from Non-Controlling Interests stood at $15.8 million in 2021, then surged by 827.4% to $146.2 million in 2022, then tumbled by 79.58% to $29.8 million in 2023.
• Business Quant data shows VERA's Income from Non-Controlling Interests at $29.8 million in Q1 2023, $146.2 million in Q4 2022, and -$24.8 million in Q3 2022.